Bharat Biotech has submitted Covaxin's Phase III trial data to DCGI: Govt sources

Credit: IndiaTimes- Published on June 21, 2021

Video credit: Oneindia
Published on June 22, 2021 -  02:02
Bharat biotech submits phase 3 trial data, expert panel meet today| Covaxin | Oneindia News
Bharat Biotech has submitted Phase 3 clinical trial data for its Covid-19 vaccine, Covaxin, to the Drug Controller General of India (DCGI). The development comes nearly five months after Covaxin was authorised for emergency usage in the country. #Covid19 #BharatBiotech #Covaxin

You are here

💡 newsR Knowledge: Other News Mentions

Bharat Biotech

Indian biotechnology company and vaccine manufacturer
After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa..
Credit: IndiaTimes - Published 5 days ago

Credit: IndiaTimes - Published 6 days ago

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s..
Credit: IndiaTimes - Published 6 days ago


Vaccine against COVID-19
Credit: IndiaTimes - Published 10 hours ago

An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
Credit: IndiaTimes - Published 4 days ago

Related videos from verified sources

Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News 02:03
Credit: Oneindia - Published on June 22, 2021 

Related news from verified sources

Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the...
on June 22, 2021 • IndiaTimes

You might like